Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $248,220.00 in Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,730 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $14.00, for a total transaction of $248,220.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at approximately $1,262,520. The trade was a 16.43% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total transaction of $31,780.00.
• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total transaction of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.02, for a total transaction of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total transaction of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Price Performance

Shares of DRTS traded down $0.63 during trading hours on Wednesday, hitting $13.64. 278,117 shares of the stock were exchanged, compared to its average volume of 591,397. The stock’s 50-day moving average price is $11.68 and its two-hundred day moving average price is $9.23. Alpha Tau Medical Ltd. has a 12-month low of $3.00 and a 12-month high of $14.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -13.12 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.14 million. Research analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Friday, July 17th. LADENBURG THALM/SH SH boosted their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Piper Sandler raised their target price on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 19th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.80.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Trifecta Capital Advisors LLC acquired a new stake in Alpha Tau Medical during the fourth quarter worth $48,000. Envestnet Asset Management Inc. acquired a new position in shares of Alpha Tau Medical in the 3rd quarter valued at $62,000. Bank of America Corp DE grew its holdings in shares of Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after purchasing an additional 21,677 shares during the period. Wells Fargo & Company MN increased its position in shares of Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Everhart Financial Group Inc. acquired a new stake in shares of Alpha Tau Medical during the 2nd quarter worth about $126,000. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.